{
  "success": true,
  "pagesUsed": [
    2,
    3,
    4,
    5,
    6,
    7,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    19,
    20,
    21,
    22,
    24,
    25,
    26,
    27,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    40,
    41,
    42,
    43,
    44,
    45,
    46,
    47,
    48
  ],
  "modelUsed": "gemini-2.5-pro",
  "interventions": {
    "studyInterventions": [
      {
        "id": "int_1",
        "name": "ALXN1840",
        "type": {
          "id": "01410a58-2afa-424e-8260-446f32199fb0",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "role": {
          "id": "0c2ae278-9277-4b30-ac21-4554530edafa",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "ALXN1840 (bis-choline tetrathiomolybdate; formerly known as WTX101) is a novel copper binding agent in development for the treatment of Wilson disease (WD).",
        "productIds": [
          "prod_1"
        ],
        "administrationIds": [
          "admin_1"
        ]
      },
      {
        "id": "int_2",
        "name": "Paracetamol/acetaminophen",
        "type": {
          "id": "ea7071f5-adb3-41d6-8fc4-fc2acc0fd2b6",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "4b3d9118-ad68-497d-9a3a-96974f4b348d",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Permitted for use as an exception with the approval of the Investigator at doses of a maximum 1000 mg per day.",
        "administrationIds": [
          "admin_2"
        ]
      },
      {
        "id": "int_3",
        "name": "Ibuprofen",
        "type": {
          "id": "c7452fbf-8372-4311-aad6-22cc9e816768",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "f39e63c5-5f30-415b-b7d6-7f31090f54c8",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Permitted for use with caution and approval of the Investigator. The dose must not exceed 1200 mg in any 24-hour period.",
        "administrationIds": [
          "admin_3"
        ]
      }
    ],
    "administrableProducts": [
      {
        "id": "prod_1",
        "name": "ALXN1840",
        "administrableDoseForm": {
          "id": "2b3a5a76-8939-430d-8be9-722ce1935446",
          "code": "C42998",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Tablet",
          "standardCode": {
            "id": "461c2266-3ba2-4d16-b1d6-8d92de75a0fe",
            "code": "C42998",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Tablet",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "8b9c3edb-ac22-4322-8969-117e0e0036d2",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "15 mg",
        "substanceIds": [
          "sub_1"
        ],
        "manufacturer": "Alexion"
      }
    ],
    "administrations": [
      {
        "id": "admin_1",
        "name": "ALXN1840 initial dose",
        "instanceType": "Administration",
        "dose": "15 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Approximately 28 days (Day 1 through Day 28)"
      },
      {
        "id": "admin_2",
        "name": "ALXN1840 titrated dose",
        "instanceType": "Administration",
        "dose": "30 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "From Day 29 through Day 39"
      },
      {
        "id": "admin_3",
        "name": "ALXN1840 dose reduction",
        "instanceType": "Administration",
        "dose": "15 mg",
        "doseFrequency": "every other day",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Dose modification for specific adverse events until resolution of abnormality."
      }
    ],
    "substances": [
      {
        "id": "sub_1",
        "name": "bis-choline tetrathiomolybdate",
        "instanceType": "Substance",
        "description": "Active ingredient of ALXN1840. Also referred to as WTX101."
      },
      {
        "id": "sub_2",
        "name": "tetrathiomolybdic acid",
        "instanceType": "Substance",
        "description": "Each 15 mg ALXN1840 tablet contains 7.8 mg of tetrathiomolybdic acid."
      }
    ],
    "medicalDevices": [],
    "summary": {
      "interventionCount": 3,
      "productCount": 1,
      "deviceCount": 0
    }
  },
  "rawResponse": {
    "interventions": [
      {
        "name": "ALXN1840",
        "role": "Investigational Product",
        "description": "ALXN1840 (bis-choline tetrathiomolybdate; formerly known as WTX101) is a novel copper binding agent in development for the treatment of Wilson disease (WD)."
      },
      {
        "name": "Paracetamol/acetaminophen",
        "role": "Concomitant Medication",
        "description": "Permitted for use as an exception with the approval of the Investigator at doses of a maximum 1000 mg per day."
      },
      {
        "name": "Ibuprofen",
        "role": "Concomitant Medication",
        "description": "Permitted for use with caution and approval of the Investigator. The dose must not exceed 1200 mg in any 24-hour period."
      }
    ],
    "products": [
      {
        "name": "ALXN1840",
        "doseForm": "Tablet",
        "strength": "15 mg",
        "manufacturer": "Alexion"
      }
    ],
    "substances": [
      {
        "name": "bis-choline tetrathiomolybdate",
        "description": "Active ingredient of ALXN1840. Also referred to as WTX101."
      },
      {
        "name": "tetrathiomolybdic acid",
        "description": "Each 15 mg ALXN1840 tablet contains 7.8 mg of tetrathiomolybdic acid."
      }
    ],
    "administrations": [
      {
        "name": "ALXN1840 initial dose",
        "dose": "15 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "Approximately 28 days (Day 1 through Day 28)"
      },
      {
        "name": "ALXN1840 titrated dose",
        "dose": "30 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "From Day 29 through Day 39"
      },
      {
        "name": "ALXN1840 dose reduction",
        "dose": "15 mg",
        "frequency": "every other day",
        "route": "Oral",
        "duration": "Dose modification for specific adverse events until resolution of abnormality."
      }
    ],
    "devices": []
  }
}